Current perspectives on pharmacotherapy of Alzheimer's disease

Bibliography

• Campbell VA, Gowran A. Alzheimer's disease: taking the edge off with cannabinoids? Br J Pharmacol 2007;152(5):655
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin N Am 2005;15(4):727-53
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid in Alzheimer's disease. Nat Rev Neurosci 2007;8(7):499-509
   PubMed Web of Science ®Google Scholar
• Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Ann Rev Med 2006;57:513-33
   PubMed Web of Science ®Google Scholar
• Schmitt B, Bernhardt T, Moeller HJ, Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs 2004;18(13):827-44
   PubMed Web of Science ®Google Scholar
• Deutsch JA, Rocklin KW. Amnesia induced by scopolamine and its temporal variations. Nature 1967;216:89-90
   PubMed Web of Science ®Google Scholar
• Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982;139(11):1421-9
   PubMed Web of Science ®Google Scholar
• Van Marum RJ. Current and future therapy in Alzheimer's disease. Fund Clin Pharmacol 2008;22(3):265-74
   PubMed Web of Science ®Google Scholar
• Shah RS, Lee HG, Xiongwei Z, Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008;62(4):199-207
   PubMed Web of Science ®Google Scholar
• Qizilbash N, Schneider LS. Practical recommendations and opinions on therapies for cognitive symptoms and prognosis modification. Evidence-based dementia practice. Blackwell, London; 2002. p. 560-588
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3):317-24
   PubMed Web of Science ®Google Scholar
• Chuah LYM, Chong DL, Chen AK, Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep 2009;32(8):999-1010
   PubMed Web of Science ®Google Scholar
• Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. J Drug Design Dev Ther 2008;2:245-54
   Google Scholar
• Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer disease & associated disorders 2003;17(3):105-12
   Google Scholar
• Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatrics 2009;21(05):813-24
   PubMedGoogle Scholar
• Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2005;9(01):101-24
   PubMedGoogle Scholar
• Mori E, Hashimoto M, Ranga Krishnan K, Murali Doraiswamy P. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer disease & associated disorders 2006;20:S19-23
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurol 2007;6(8):734-46
   PubMed Web of Science ®Google Scholar
• Atamna H, Nguyen A, Schultz C, Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008;22(3):703
   PubMed Web of Science ®Google Scholar
• Mulugeta E, Karlsson E, Islam A, Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003;960(1-2):259-62
   PubMed Web of Science ®Google Scholar
• Kamal MA, Klein P, Yu Q, Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimer's Dis 2006;10(1):43-51
   PubMed Web of Science ®Google Scholar
• Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimer's Dis 2006;10(1):81-7
   PubMed Web of Science ®Google Scholar
• Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;61(6):473-81
   PubMed Web of Science ®Google Scholar
• Lorrio S, Negredo P, Roda JM, Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res 2009;1254:128-37
   PubMed Web of Science ®Google Scholar
• Lee H, Zhu X, Nunomura A, Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006;3(1):75-80
   PubMedGoogle Scholar
• Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5(9):677-85
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. Abeta Oligomers: a decade of discovery. J Neurochem 2007;101(5):1172-8
   PubMed Web of Science ®Google Scholar
• Luo Y, Bolon B, Kahn S, Mice deficient in BACE1, the Alzheimer's -secretase, have normal phenotype and abolished-amyloid generation. Nat Neurosci 2001;4(3):231-2
   PubMed Web of Science ®Google Scholar
• Sastre M, Dewachter I, Rossner S. Nonsteroidal antiinflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc Natl Acad Sci 2006;103:443-8
   PubMed Web of Science ®Google Scholar
• Watson G, Cholerton BA, Reger MA, Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatric Psych 2005;13(11):950-6
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JFB, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6(4):246-54
   PubMed Web of Science ®Google Scholar
• Strum JC, Shehee R, Virley D, Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimer's Dis 2007;11(1):45-51
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, NSAIDs and enantiomers of flurbiprofen target -secretase and lower A 42 in vivo. J Clin Invest 2003;112(3):440-9
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Black SE, Hendrix SB, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Curr Neurol Neurosci Rep 2008;7(8):483-93
   Google Scholar
• Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: are they effective? P T 2010;35(4):208-11
   PubMedGoogle Scholar
• Imbimbo BP. Why did tarenflurbil fail in Alzheimer's disease? J Alzheimer's Dis 2009;17(4):757-60
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease. Curr Opin Invest Drugs 2009;10(7):721
   PubMedGoogle Scholar
• Wolfe MS. Inhibition and modulation of [gamma]-Secretase for Alzheimer's disease. Neurotherapeutics 2008;5(3):391-8
   PubMed Web of Science ®Google Scholar
• Fahrenholz F, Postina R. Secretase activation–an approach to Alzheimer's disease therapy. Neurodegenerative Dis 2006;3(4-5):255-61
   PubMed Web of Science ®Google Scholar
• Fisher A, Pittel Z, Haring R, M 1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease. J Mol Neurosci 2003;20(3):349-56
   PubMed Web of Science ®Google Scholar
• Solomon B. Antibody-mediated immunotherapy for Alzheimer's disease. Curr Opin Invest Drugs 2007;8(7):519-24
   PubMedGoogle Scholar
• Gilman S, Koller M, Black RS, Clinical effects of A {beta} immunization (AN1792) in patients with AD in an interrupted trial. Neurol 2005;64(9):1553-60
   PubMed Web of Science ®Google Scholar
• Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009;7(1):7-13
   PubMedGoogle Scholar
• Holmes C, Boche D, Wilkinson D, Long-term effects of A [beta] 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, Safety and changes in plasma and cerebrospinal fluid amyloid [beta] after a single administration of an amyloid [beta] monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2005;33(2):67-73
   Google Scholar
• Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A [beta] levels. Neurobiol Aging 2008;29(2):210-21
   PubMed Web of Science ®Google Scholar
• Saito T, Iwata N, Tsubuki S. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005;11:434-9
   PubMed Web of Science ®Google Scholar
• Eckman EA, Watson M, Marlow L, Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278(4):2081-8
   PubMed Web of Science ®Google Scholar
• Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007;6(4):373-8
   PubMed Web of Science ®Google Scholar
• Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid [beta]-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007;26(1):273-81
   PubMed Web of Science ®Google Scholar
• Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimers disease. Curr Alzheimer Res 2007;4(2):191-7
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Zlokovic BV. RAGE (Yin) versus LRP (Yang) balance regulates alzheimer amyloid (beta)-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35:2628-31
   PubMed Web of Science ®Google Scholar
• Chen X, Walker DG, Schmidt AM, RAGE: a potential target for A beta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007;7(8):735-43
   PubMed Web of Science ®Google Scholar
• Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimers disease. Curr Drug Targets 2004;5(6):535-51
   PubMed Web of Science ®Google Scholar
• Dedeoglu A, Cormier K, Payton S, Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004;39(11):1641-49
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and Alzheimer's disease. Exp Opin Invest Drugs 2004;13(12):1585-92
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H, Safety, efficacy, and biomarker findings of PBT2 in targeting A [beta] as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7(9):779-86
   PubMed Web of Science ®Google Scholar
• Frisardi V, Solfrizzi V, Imbimbo PB, Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 2010;7(1):40-55
   PubMed Web of Science ®Google Scholar
• Bonda DJ, Wang X, Perry G, Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacol 2010;59(4-5):290-4
   PubMed Web of Science ®Google Scholar
• Singh M, Arseneault M, Sanderson T, Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008;56(13):4855-73
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Cole GM, A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005;2(2):131-39
   PubMedGoogle Scholar
• Sahoo DK, Roy A, Chainy GBN. Protective effects of vitamin E and curcumin on L-thyroxine-induced rat testicular oxidative stress. Chem Biol Interact 2008;176(2-3):121-8
   PubMed Web of Science ®Google Scholar
• Wei QY, Chen WF, Zhou B, Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochimica et Biophysica Acta (BBA)-General Subjects 2006;1760(1):70-7
   PubMed Web of Science ®Google Scholar
• Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimer's Dis 2004;6(4):367-77
   PubMed Web of Science ®Google Scholar
• Nishinaka T, Ichijo Y, Ito M, Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett 2007;170(3):238-47
   PubMed Web of Science ®Google Scholar
• Ishrat T, Hoda MN, Khan MB, Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009;19(9):636-47
   PubMed Web of Science ®Google Scholar
• Sandur SK, Ichikawa H, Pandey MK, Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Rad Biol Med 2007;43(4):568-80
   PubMed Web of Science ®Google Scholar
• Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol 2007;576(1-3):34-42
   PubMed Web of Science ®Google Scholar
• Bengmark S. Curcumin, an atoxic antioxidant and natural NF (kappa) B, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN 2006;30(1):45-55
   PubMed Web of Science ®Google Scholar
• Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009;11(11):2851-62
   PubMed Web of Science ®Google Scholar
• Ono K, Hamaguchi T, Naiki H, Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. BiochimBiophys Acta (BBA)-Molecular Basis of Disease 2006;1762(6):575-86
   PubMed Web of Science ®Google Scholar
• Lindsay J, Laurin D, Verreault R, Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156(5):445-54
   PubMed Web of Science ®Google Scholar
• Mokni M, Elkahoui S, Limam F, Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochemical Res 2007;32(6):981-7
   PubMed Web of Science ®Google Scholar
• Ates O, Cayli S, Altinoz E, Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007;294(1):137-44
   PubMed Web of Science ®Google Scholar
• Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005;280:37377-37382
   PubMed Web of Science ®Google Scholar
• Candelario-Jalil E, de Oliveira ACP, Graf S, Resveratrol potently reduces prostaglandin E 2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 2007;4(1):25-34
   PubMedGoogle Scholar
• Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006;72(11):1439-52
   PubMed Web of Science ®Google Scholar
• Sharma M, Briyal S, Gupta YK. Effect of alpha lipoic acid, melatonin and trans resveratrol on intracerebroventricular streptozotocin induced spatial memory deficit in rats. Ind J Physiol Pharmacol 2005;49(4):395-404
   PubMedGoogle Scholar
• Mandel S, Amit T, Reznichenko L, Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res 2006;50(2):229-34
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao Z, Moderate consumption of Cabernet Sauvignon attenuates A (beta) neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006;20(13):2313-19
   PubMed Web of Science ®Google Scholar
• Karuppagounder SS, Pinto JT, Xu H, Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009;54(2):111-18
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Arendash GW, Hou H, Green tea epigallocatechin-3-gallate (EGCG) reduces [beta]-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008;1214:177-87
   PubMed Web of Science ®Google Scholar
• Levites Y, Amit T, Youdim MBH, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 2002;277(34):30574-80
   PubMed Web of Science ®Google Scholar
• Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection and neurorescue against A toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003;17(8):952-4
   PubMedGoogle Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Structural Mol Biol 2008;15(6):558-66
   PubMed Web of Science ®Google Scholar
• Haque AM, Hashimoto M, Katakura M, Green tea catechins prevent cognitive deficits caused by A [beta] 1-40 in rats. J Nutr Biochem 2008;19(9):619-26
   PubMed Web of Science ®Google Scholar
• Choi J, Conrad CC, Dai R, Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics 2003;3(1):73-7
   PubMed Web of Science ®Google Scholar
• Sung S, Yao Y, Uryr K, Early vitamin E supplementation in young but not aged mice reduces A-beta levels and amlyoid deposition in a transgenic model of AD. FASEB J 2004;18:323-5
   PubMed Web of Science ®Google Scholar
• Khanna S, Roy S, Ryu H, Molecular basis of vitamin E action. Tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem 2003;278(44):43508-15
   PubMed Web of Science ®Google Scholar
• Pearce BC, Parker RA, Deason ME, Inhibitors of cholesterol biosynthesis. 2. hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogs of the tocotrienols. J Med Chem 1994;37(4):526-41
   PubMed Web of Science ®Google Scholar
• Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Rad Biol Med 1991;10(5):263-75
   PubMed Web of Science ®Google Scholar
• Tiwari V, Kuhad A, Bishnoi M, Chopra K. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative–nitrosative stress in rats. Pharmacol Biochem Behav 2009;93(2):183-9
   PubMed Web of Science ®Google Scholar
• Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of NF-[kappa][beta] signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav 2009;92(2):251-9
   PubMed Web of Science ®Google Scholar
• Frank B, Gupta S. A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 2005;17(4):269-86
   PubMedGoogle Scholar
• Clostre F. Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year. Ann Pharm Fr 1999;1:S18-88
   Google Scholar
• DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions basic studies and clinical applications. Curr Drug Targets 2000;1(1):25-58
   PubMedGoogle Scholar
• Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr 2007;137(1):183S-185S
   Web of Science ®Google Scholar
• Surh Y, Lee J, Choi K, Ko S. Effects of selected ginsenosides on phorbol ester-induced expression of cyclooxygenase-2 and activation of NF-kappaB and ERK1/2 in mouse skin. Ann N Y Acad Sci 2004;973:396-401
   Web of Science ®Google Scholar
• Li N, Liu B, Dluzen DE, Jin Y. Protective effects of ginsenoside Rg2 against glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007;111(3):458-63
   PubMed Web of Science ®Google Scholar
• Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Safety 2002;25(5):323-44
   PubMed Web of Science ®Google Scholar
• Trombino S, Serini S, Di Nicuolo F, Antioxidant effect of ferulic acid in isolated membranes and intact cells: synergistic interactions with alpha-tocopherol, beta-carotene, and ascorbic acid. J Agri Food Chem 2004;52(8):2411-20
   PubMed Web of Science ®Google Scholar
• Mamiya T, Kise M, Morikawa K. Ferulic acid attenuated cognitive deficits and increase in carbonyl proteins induced by buthionine-sulfoximine in mice. Neurosci Lett 2008;430(2):115-18
   PubMed Web of Science ®Google Scholar
• Islam M, Yoshida H, Matsuki N, Antioxidant, free radical-scavenging, and NF-kappa B-inhibitory activities of phytosteryl ferulates: structure-activity studies. J Pharmacol Sci 2009;111(4):328-37
   PubMed Web of Science ®Google Scholar
• Das A, Shanker G, Nath C, A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 2002;73(4):893-900
   PubMed Web of Science ®Google Scholar
• Hota SK, Barhwal K, Baitharu I, Bacopa monniera leaf extract ameliorates hypobaric hypoxia induced spatial memory impairment. Neurobiol Dis 2009;34(1):23-39
   PubMed Web of Science ®Google Scholar
• Fuller S, Steele M, Imholz P, Münch G. Activated astroglia during chronic inflammation in Alzheimer's disease – do they neglect their neurosupportive roles? Mutation research/fundamental and molecular mechanisms of mutagenesis 2010;649(2):40-9
   Google Scholar
• Breitner JCS, Gau BA, Welsh KA, Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurol 1994;44(2):227-35
   PubMed Web of Science ®Google Scholar
• Galimberti D, Scarpini E. Treatment of Alzheimer's disease: symptomatic and disease-modifying approaches. Curr Aging Sci 2010;3(1):46-56
   PubMedGoogle Scholar
• Kuller LH. Statins and dementia. Curr atheroscler Rep 2007;9(2):154-61
   PubMedGoogle Scholar
• Siegel GJ, Chauhan NB, Feinstein DL, Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurol 2008;71(5):383-91
   PubMed Web of Science ®Google Scholar
• Leroy K, Ando K, Héraud C, Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis 2010;19(2):705-19
   PubMed Web of Science ®Google Scholar
• Butler D, Bendiske J, Michaelis ML, Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 2007;562(1-2):20-7
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ, A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exper Ther 2008;325(1):146
   PubMed Web of Science ®Google Scholar
• Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A (beta) or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007;170(5):1669
   PubMed Web of Science ®Google Scholar
• Maki PM, Gast MJ, Vieweg AJ, Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurol 2007;69(13):1322
   PubMed Web of Science ®Google Scholar
• Casadesus G, Milliken EL, Webber KM, Increases in luteinizing hormone are associated with declines in cognitive performance. Mol Cell Endocrinol 2007;269(1-2):107-11
   PubMed Web of Science ®Google Scholar
• Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003;17(1):27-45
   PubMed Web of Science ®Google Scholar
• Planel E, Tatebayashi Y, Miyasaka T, Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 2007;27(50):13635
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372(9634):207-15
   PubMed Web of Science ®Google Scholar
• Trial C, Gandy SE. Dimebon Disappoints: is there hope for novel Alzheimer's agent? 2010. Available from: www.medscape.com/viewarticle/718401
   Google Scholar
• Lim GP, Calon F, Morihara T, A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25(12):3032
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, (Omega)-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD Study: a randomized double-blind trial. Arch Neurol 2006;63(10):1402-9
   PubMedGoogle Scholar
• Xaliproden (Xalprila) for Alzheimer's disease. National Horizon Scanning Centre 2007 [Cited April 2010]. Available from: www.haps.bham.ac.uk/publichealth/horizon/outputs/ documents/2007/april/Xaliproden.pdf
   Google Scholar
• Douillet P, Orgogozo JM. What we have learned from the xaliproden Sanofi-aventis trials. J Nutr Health Aging 2009;13(4):365-366
   PubMed Web of Science ®Google Scholar